(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 November 2014 (20.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/184143 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C07K 19/00* (2006.01)
C12N 15/63 (2006.01) *C07K 14/725* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2014/059662

(22) International Filing Date:
12 May 2014 (12.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/US2013/040755 13 May 2013 (13.05.2013) US
13/892,805 13 May 2013 (13.05.2013) US
PCT/US2013/040766 13 May 2013 (13.05.2013) US
61/888,259 8 October 2013 (08.10.2013) US

(71) Applicant: **CELLECTIS** [FR/FR]; 8 Rue de la Croix Jarry, F-75013 Paris (FR).

(72) Inventors: **GALETTO, Roman**; 18, rue des Commines, F-75003 Paris (FR). **SMITH, Julianne**; Villa Raffaela, 13 rue de la ferme, F-92350 Le Plessis Robinson (FR). **SCHARENBERG, Andrew**; 1222 NW Norcross Way, Seattle, Washington 98177 (US). **MANNIOUI, Cècile**; 8 bis, rue Maurice Roy, F-94350 Villiers-sur-Marne (FR).

(74) Agent: **ZACCO DENMARK A/S**; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF

(57) Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged "activated" state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.




Figure 1

WO 2014/184143 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*